Valuation check: ACAD's profit margin is 33.42%, above the Healthcare sector average of 13.89%.
Get informed when a big investor buys or sells
+ FollowAs of Jun 2026
Trailing 12 months ending Jun 2026
The latest profit margin for ACAD is 33.42% as of June 2026. That compares with 21.8% in the prior-year period — up 53.3% year over year. That is above the Healthcare sector average of 13.89%. Investors often review this figure alongside Acadia Pharmaceuticals's historical trend and sector peers before judging valuation or financial health.
Over the past year, ACAD's profit margin moved from 21.8% to 33.42% — a 53.3% year-over-year increase. If the trend continues in the same direction for several quarters, it can signal a meaningful shift in Acadia Pharmaceuticals's valuation or profitability profile.
Against Healthcare companies, ACAD currently prints 33.42% for profit margin, while the sector average sits near 13.89%. That is roughly 140.5% above the sector mean. Large gaps often invite a closer look at Acadia Pharmaceuticals's growth, margins, and balance sheet.
Profit Margin shows how effectively Acadia Pharmaceuticals converts resources into returns. At 33.42%, ACAD may look efficient or underperforming depending on peer benchmarks and trend direction. That compares with 21.8% in the prior-year period — up 53.3% year over year. Pair the percentage with revenue growth and leverage for a fuller health check.
After noting ACAD's profit margin (33.42%), review year-over-year change from 21.8%, peer averages, and a few neighboring metrics such as revenue, margins, or valuation multiples. That combination usually beats staring at a single figure. The navigation links on this page jump you to those related views.